Compare Heron Therapeutics Inc (HRTX) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Progressive Corp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Progressive Corp trades at $218.73 (market cap $124.28B). The key difference: Progressive Corp is far larger — about 1678.6× Heron Therapeutics Inc's market cap, and Progressive Corp pays a 0.19% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Progressive Corp for 81 Days on average.
| HRTX | PGR | |
|---|---|---|
Market Cap | $74.04M | $124.28B |
Volume | 3,668,095 | 2,551,191 |
Sector | Health | Financials |
52-Week High | $1.49 | $242.16 |
52-Week Low | $0.27 | $190.40 |
Typical Hold Time | 35 Days | 81 Days |
Enterprise Value | $180.78M | $132.48B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
PGR trades at $218.73, up 3.15% today, with a bullish technical signal from moving averages and strong fundamentals including a 12.85% net income margin and 34.94% ROE. Revenue grew from $49.6B in 2022 to $87.6B in 2025, with net income surging to $11.3B. The company recently announced a $0.10 dividend payable in October 2026, and Q2 2026 earnings beat expectations.
The outlook is positive given robust earnings growth and analyst consensus price target of $222.23, though risks include intensifying competition in personal auto insurance and potential market volatility. Institutional interest remains strong with recent position increases by funds like QRG Capital Management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
